Connection

JEFFREY E GERSHENWALD to Adult

This is a "connection" page, showing publications JEFFREY E GERSHENWALD has written about Adult.
Connection Strength

0.486
  1. Stemming the Rising Incidence of Melanoma: Calling Prevention to Action. J Natl Cancer Inst. 2016 Jan; 108(1).
    View in: PubMed
    Score: 0.020
  2. Randomized controlled trial of a sun protection intervention for children of melanoma survivors. Cancer Epidemiol Biomarkers Prev. 2013 Oct; 22(10):1813-24.
    View in: PubMed
    Score: 0.017
  3. Sentinel-lymph-node biopsy for cutaneous melanoma. N Engl J Med. 2011 May 05; 364(18):1738-45.
    View in: PubMed
    Score: 0.015
  4. Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. J Clin Oncol. 2008 Sep 10; 26(26):4296-303.
    View in: PubMed
    Score: 0.012
  5. Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma. Cancer. 2006 Dec 01; 107(11):2647-52.
    View in: PubMed
    Score: 0.011
  6. Acne vulgaris: false-positive finding on integrated 18F-FDG PET/CT in a patient with melanoma. AJR Am J Roentgenol. 2006 Jul; 187(1):W117-9.
    View in: PubMed
    Score: 0.011
  7. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol. 2005 Aug; 12(8):587-96.
    View in: PubMed
    Score: 0.010
  8. Health Economic Consequences Associated With COVID-19-Related Delay in Melanoma Diagnosis in Europe. JAMA Netw Open. 2024 02 05; 7(2):e2356479.
    View in: PubMed
    Score: 0.009
  9. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol. 2003 Jun; 10(5):569-74.
    View in: PubMed
    Score: 0.009
  10. Patterns of regional and distant metastasis in patients with conjunctival melanoma: experience at a cancer center over four decades. Ophthalmology. 2001 Nov; 108(11):2101-5.
    View in: PubMed
    Score: 0.008
  11. Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram. J Clin Oncol. 2020 08 20; 38(24):2719-2727.
    View in: PubMed
    Score: 0.007
  12. Regional nodal basin control is not compromised by previous sentinel lymph node biopsy in patients with melanoma. Ann Surg Oncol. 2000 Apr; 7(3):226-31.
    View in: PubMed
    Score: 0.007
  13. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. Ann Surg Oncol. 2000 Mar; 7(2):160-5.
    View in: PubMed
    Score: 0.007
  14. Circulating Tumor Cells and Early Relapse in Node-positive Melanoma. Clin Cancer Res. 2020 04 15; 26(8):1886-1895.
    View in: PubMed
    Score: 0.007
  15. Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. J Clin Oncol. 2020 05 01; 38(13):1429-1441.
    View in: PubMed
    Score: 0.007
  16. FOXD3 Regulates VISTA Expression in Melanoma. Cell Rep. 2020 01 14; 30(2):510-524.e6.
    View in: PubMed
    Score: 0.007
  17. KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncol. 2020 Jan; 16(3):4429-4438.
    View in: PubMed
    Score: 0.007
  18. Quantitative associations between health insurance and stage of melanoma at diagnosis among nonelderly adults in the United States. Cancer. 2020 02 15; 126(4):775-781.
    View in: PubMed
    Score: 0.007
  19. Correlation of Tumor Burden in Sentinel Lymph Nodes with Tumor Burden in Nonsentinel Lymph Nodes and Survival in Cutaneous Melanoma. Clin Cancer Res. 2019 12 15; 25(24):7585-7593.
    View in: PubMed
    Score: 0.007
  20. Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. Mod Pathol. 2020 03; 33(3):496-513.
    View in: PubMed
    Score: 0.007
  21. Complex General Surgical Oncology Fellowship Applicants: Trends over Time and the Impact of Board Certification Eligibility. Ann Surg Oncol. 2019 Sep; 26(9):2667-2674.
    View in: PubMed
    Score: 0.006
  22. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 11; 24(11):1649-1654.
    View in: PubMed
    Score: 0.006
  23. Synchronous elective contralateral mastectomy and immediate bilateral breast reconstruction in women with early-stage breast cancer. Ann Surg Oncol. 1998 Sep; 5(6):529-38.
    View in: PubMed
    Score: 0.006
  24. Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery. 1998 Aug; 124(2):203-10.
    View in: PubMed
    Score: 0.006
  25. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol. 1998 Jun; 16(6):2253-60.
    View in: PubMed
    Score: 0.006
  26. Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clin Cancer Res. 2018 09 15; 24(18):4416-4428.
    View in: PubMed
    Score: 0.006
  27. Clinical impact of ulceration width, lymphovascular invasion, microscopic satellitosis, perineural invasion, and mitotic rate in patients undergoing sentinel lymph node biopsy for cutaneous melanoma: a retrospective observational study at a comprehensive cancer center. Cancer Med. 2018 03; 7(3):583-593.
    View in: PubMed
    Score: 0.006
  28. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018 03; 19(3):310-322.
    View in: PubMed
    Score: 0.006
  29. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193.
    View in: PubMed
    Score: 0.006
  30. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med. 2017 06 08; 376(23):2211-2222.
    View in: PubMed
    Score: 0.006
  31. Association between Body Mass Index, C-Reactive Protein Levels, and Melanoma Patient Outcomes. J Invest Dermatol. 2017 08; 137(8):1792-1795.
    View in: PubMed
    Score: 0.006
  32. Clinicopathological features and clinical outcomes associated with TP53 and BRAFNon-V600 mutations in cutaneous melanoma patients. Cancer. 2017 04 15; 123(8):1372-1381.
    View in: PubMed
    Score: 0.005
  33. Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases. Clin Cancer Res. 2017 04 15; 23(8):2093-2104.
    View in: PubMed
    Score: 0.005
  34. Sex Differences in Age at Primary Melanoma Diagnosis in a Population-Based Analysis (US?Surveillance, Epidemiology, and End Results, 2005-2011). J Invest Dermatol. 2016 09; 136(9):1894-1897.
    View in: PubMed
    Score: 0.005
  35. Correlates of Sun Protection and Sunburn in Children of Melanoma Survivors. Am J Prev Med. 2016 09; 51(3):e77-85.
    View in: PubMed
    Score: 0.005
  36. 4-nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma: a case-control analysis. Melanoma Res. 2016 Apr; 26(2):181-7.
    View in: PubMed
    Score: 0.005
  37. Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein. J Clin Oncol. 2016 05 20; 34(15):1741-7.
    View in: PubMed
    Score: 0.005
  38. Elevated Serum Leptin Levels are Associated With an Increased Risk of Sentinel Lymph Node Metastasis in Cutaneous Melanoma. Medicine (Baltimore). 2016 Mar; 95(11):e3073.
    View in: PubMed
    Score: 0.005
  39. Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy. J Clin Oncol. 2016 Apr 01; 34(10):1079-86.
    View in: PubMed
    Score: 0.005
  40. Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma. Clin Cancer Res. 2016 06 15; 22(12):3016-24.
    View in: PubMed
    Score: 0.005
  41. CDC Grand Rounds: Prevention and Control of Skin Cancer. MMWR Morb Mortal Wkly Rep. 2015 Dec 04; 64(47):1312-4.
    View in: PubMed
    Score: 0.005
  42. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Hum Pathol. 2015 Aug; 46(8):1101-10.
    View in: PubMed
    Score: 0.005
  43. Is surviving enough? Coping and impact on activities of daily living among melanoma patients with lymphoedema. Eur J Cancer Care (Engl). 2015 Sep; 24(5):724-33.
    View in: PubMed
    Score: 0.005
  44. C-reactive protein as a marker of melanoma progression. J Clin Oncol. 2015 Apr 20; 33(12):1389-96.
    View in: PubMed
    Score: 0.005
  45. Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. Clin Cancer Res. 2014 Nov 01; 20(21):5527-36.
    View in: PubMed
    Score: 0.005
  46. Is surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage-specific surveillance strategies. Ann Surg. 2014 Jun; 259(6):1215-22.
    View in: PubMed
    Score: 0.005
  47. Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. Ann Surg Oncol. 2014 Apr; 21(4):1075-81.
    View in: PubMed
    Score: 0.004
  48. Impact of the 2009 (7th edition) AJCC melanoma staging system in the classification of thin cutaneous melanomas. Biomed Res Int. 2013; 2013:898719.
    View in: PubMed
    Score: 0.004
  49. Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma. Cancer. 2013 Nov 01; 119(21):3821-9.
    View in: PubMed
    Score: 0.004
  50. Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol. 2013 Nov; 20(12):3961-8.
    View in: PubMed
    Score: 0.004
  51. Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47). Clin Cancer Res. 2013 Jul 01; 19(13):3611-20.
    View in: PubMed
    Score: 0.004
  52. Polymorphisms of nucleotide excision repair genes predict melanoma survival. J Invest Dermatol. 2013 Jul; 133(7):1813-21.
    View in: PubMed
    Score: 0.004
  53. Influence of single nucleotide polymorphisms in the MMP1 promoter region on cutaneous melanoma progression. Melanoma Res. 2012 Apr; 22(2):169-75.
    View in: PubMed
    Score: 0.004
  54. The expression of p-STAT3 in stage IV melanoma: risk of CNS metastasis and survival. Oncotarget. 2012 Mar; 3(3):336-44.
    View in: PubMed
    Score: 0.004
  55. A novel and accurate computer model of melanoma prognosis for patients staged by sentinel lymph node biopsy: comparison with the American Joint Committee on Cancer model. J Am Coll Surg. 2012 Apr; 214(4):608-17; discussion 617-9.
    View in: PubMed
    Score: 0.004
  56. Mapping FACT-melanoma quality-of-life scores to EQ-5D health utility weights. Value Health. 2011 Sep-Oct; 14(6):900-6.
    View in: PubMed
    Score: 0.004
  57. Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database. Ann Surg Oncol. 2011 Dec; 18(13):3593-600.
    View in: PubMed
    Score: 0.004
  58. Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin Cancer Res. 2011 Jul 15; 17(14):4882-91.
    View in: PubMed
    Score: 0.004
  59. Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma. Eur J Cancer. 2011 Jan; 47(1):107-15.
    View in: PubMed
    Score: 0.003
  60. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol. 2010 Nov; 63(5):751-61.
    View in: PubMed
    Score: 0.003
  61. Prospective assessment of postoperative complications and associated costs following inguinal lymph node dissection (ILND) in melanoma patients. Ann Surg Oncol. 2010 Oct; 17(10):2764-72.
    View in: PubMed
    Score: 0.003
  62. Factors associated with false-negative sentinel lymph node biopsy in melanoma patients. Ann Surg Oncol. 2010 Mar; 17(3):709-17.
    View in: PubMed
    Score: 0.003
  63. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res. 2009 Feb; 19(1):42-9.
    View in: PubMed
    Score: 0.003
  64. Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma. Hum Mutat. 2008 Dec; 29(12):1443-51.
    View in: PubMed
    Score: 0.003
  65. Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys. 2009 Apr 01; 73(5):1376-82.
    View in: PubMed
    Score: 0.003
  66. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer. 2008 Sep 02; 99(5):734-40.
    View in: PubMed
    Score: 0.003
  67. Fibrin sealant does not decrease seroma output or time to drain removal following inguino-femoral lymph node dissection in melanoma patients: a randomized controlled trial (NCT00506311). World J Surg Oncol. 2008 Jun 18; 6:63.
    View in: PubMed
    Score: 0.003
  68. Prospective assessment of the reliability, validity, and sensitivity to change of the Functional Assessment of Cancer Therapy-Melanoma questionnaire. Cancer. 2008 May 15; 112(10):2249-57.
    View in: PubMed
    Score: 0.003
  69. Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case-control study. Int J Cancer. 2008 May 01; 122(9):2077-84.
    View in: PubMed
    Score: 0.003
  70. Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease. Cancer. 2008 May 01; 112(9):2030-7.
    View in: PubMed
    Score: 0.003
  71. Melanoma adrenal metastasis: natural history and surgical management. Am J Surg. 2008 Mar; 195(3):363-8; discussion 368-9.
    View in: PubMed
    Score: 0.003
  72. Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma. Ann Surg Oncol. 2007 Oct; 14(10):2867-75.
    View in: PubMed
    Score: 0.003
  73. Ethnic differences among patients with cutaneous melanoma. Arch Intern Med. 2006 Sep 25; 166(17):1907-14.
    View in: PubMed
    Score: 0.003
  74. Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma. J Clin Oncol. 2006 Jun 20; 24(18):2858-65.
    View in: PubMed
    Score: 0.003
  75. Invasive squamous cell carcinoma of the skin: defining a high-risk group. Ann Surg Oncol. 2006 Jul; 13(7):902-9.
    View in: PubMed
    Score: 0.003
  76. Metastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer. 2006 May 01; 106(9):2012-20.
    View in: PubMed
    Score: 0.003
  77. Genetic variants of the ADPRT, XRCC1 and APE1 genes and risk of cutaneous melanoma. Carcinogenesis. 2006 Sep; 27(9):1894-901.
    View in: PubMed
    Score: 0.003
  78. Impact of sentinel node status and other risk factors on the clinical outcome of head and neck melanoma patients. Arch Otolaryngol Head Neck Surg. 2006 Apr; 132(4):370-3.
    View in: PubMed
    Score: 0.003
  79. Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol. 2006 May; 13(5):712-20.
    View in: PubMed
    Score: 0.003
  80. In vitro sensitivity to ultraviolet B light and skin cancer risk: a case-control analysis. J Natl Cancer Inst. 2005 Dec 21; 97(24):1822-31.
    View in: PubMed
    Score: 0.003
  81. Combined-modality therapy for patients with regional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys. 2006 Jan 01; 64(1):106-13.
    View in: PubMed
    Score: 0.003
  82. Population-based assessment of surgical treatment trends for patients with melanoma in the era of sentinel lymph node biopsy. J Clin Oncol. 2005 Sep 01; 23(25):6054-62.
    View in: PubMed
    Score: 0.002
  83. Melanoma metastatic to cervical lymph nodes: Can radiotherapy replace formal dissection after local excision of nodal disease? Head Neck. 2005 Aug; 27(8):718-21.
    View in: PubMed
    Score: 0.002
  84. A critical assessment of adjuvant radiotherapy for inguinal lymph node metastases from melanoma. Ann Surg Oncol. 2004 Dec; 11(12):1079-84.
    View in: PubMed
    Score: 0.002
  85. Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer. 2004 Nov 01; 101(9):1977-86.
    View in: PubMed
    Score: 0.002
  86. Adverse events associated with the intraoperative injection of isosulfan blue. J Clin Anesth. 2004 Aug; 16(5):332-41.
    View in: PubMed
    Score: 0.002
  87. Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer. 2004 Apr 01; 100(7):1478-83.
    View in: PubMed
    Score: 0.002
  88. p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma. J Invest Dermatol. 2003 Dec; 121(6):1510-4.
    View in: PubMed
    Score: 0.002
  89. Feasibility of adjuvant hepatic arterial infusion of chemotherapy after radiofrequency ablation with or without resection in patients with hepatic metastases from colorectal cancer. Ann Surg Oncol. 2003 May; 10(4):348-54.
    View in: PubMed
    Score: 0.002
  90. Adjuvant irradiation for cervical lymph node metastases from melanoma. Cancer. 2003 Apr 01; 97(7):1789-96.
    View in: PubMed
    Score: 0.002
  91. Feasibility of preoperative lymphoscintigraphy for identification of sentinel lymph nodes in patients with conjunctival and periocular skin malignancies. Ophthalmic Plast Reconstr Surg. 2003 Mar; 19(2):102-6.
    View in: PubMed
    Score: 0.002
  92. Repair of UV light-induced DNA damage and risk of cutaneous malignant melanoma. J Natl Cancer Inst. 2003 Feb 19; 95(4):308-15.
    View in: PubMed
    Score: 0.002
  93. Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. J Clin Oncol. 2002 Dec 01; 20(23):4555-8.
    View in: PubMed
    Score: 0.002
  94. DNA repair gene XRCC3 241Met variant is not associated with risk of cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev. 2002 Oct; 11(10 Pt 1):1142-3.
    View in: PubMed
    Score: 0.002
  95. Presence of the human leukocyte antigen class II gene DRB1*1101 predicts interferon gamma levels and disease recurrence in melanoma patients. Ann Surg Oncol. 2002 Jul; 9(6):587-93.
    View in: PubMed
    Score: 0.002
  96. Adjuvant irradiation for axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys. 2002 Mar 15; 52(4):964-72.
    View in: PubMed
    Score: 0.002
  97. Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol. 2001 Dec; 8(10):766-70.
    View in: PubMed
    Score: 0.002
  98. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001 Aug 15; 19(16):3622-34.
    View in: PubMed
    Score: 0.002
  99. Significance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes. Ann Surg Oncol. 2001 Mar; 8(2):116-22.
    View in: PubMed
    Score: 0.002
  100. Surgical margins and prognostic factors in patients with thick (>4mm) primary melanoma. Ann Surg Oncol. 1998 Jun; 5(4):322-8.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.